{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:10:25Z","timestamp":1775790625807,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T17:04:15Z","timestamp":1719335055000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis"],"prefix":"10.1016","volume":"25","author":[{"given":"Helen T.","family":"Chifotides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2024.06.005_bib0001","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41598-023-49749-z","article-title":"A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis","volume":"14","author":"L\u00fcbke","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2024.06.005_bib0002","unstructured":"Bose P, Masarova L, Amin HM, Verstovsek S Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. In: Kantarjian HM, Wolff RA, Rieber AG, Eds., The MD Anderson Manual of Medical Oncology; 4th edition, McGraw Hill: China; pp 119-162."},{"issue":"4","key":"10.1016\/j.clml.2024.06.005_bib0003","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.06.005_bib0004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2013","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.06.005_bib0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.iac.2023.04.008","article-title":"KIT mutations and other genetic defects in mastocytosis","volume":"43","author":"Chantran","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.clml.2024.06.005_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"117","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.clml.2024.06.005_bib0007","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/ijd.16612","article-title":"Mastocytosis in children: a single center long-term follow-up study","volume":"62","author":"Popadic","year":"2023","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.clml.2024.06.005_bib0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.13567","article-title":"Paediatric mastocytosis: a systematic review of 1747 cases","volume":"172","author":"M\u00e9ni","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2024.06.005_bib0009","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.iac.2018.04.001","article-title":"Cutaneous mastocytosis in adults and children","volume":"38","author":"Matito","year":"2018","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.clml.2024.06.005_bib0010","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.06.005_bib0011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.iac.2023.04.011","article-title":"World Health Organization Classification and Diagnosis of Mastocytosis","volume":"43","author":"Valent","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.clml.2024.06.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Modern Pathol"},{"issue":"12","key":"10.1016\/j.clml.2024.06.005_bib0013","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International Prognostic Scoring System for Mastocytosis (IPSM): A Retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.06.005_bib0014","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.jaip.2020.05.005","article-title":"Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis","volume":"8","author":"Schwaab","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.clml.2024.06.005_bib0015","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?","volume":"148","author":"Akin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"10.1016\/j.clml.2024.06.005_bib0016","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0017","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood-2023-188617","article-title":"Decreased survival among patients with indolent systemic mastocytosis: A population-level retrospective cohort analysis using Healthcare Claims Dataset","volume":"142","author":"Mukherjee","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0018","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO Classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.clml.2024.06.005_bib0019","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal","volume":"5","author":"Valent","year":"2021","journal-title":"HemaSphere"},{"issue":"20","key":"10.1016\/j.clml.2024.06.005_bib0020","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.34420","article-title":"Patients-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM patients survey","volume":"128","author":"Mesa","year":"2022","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.06.005_bib0021","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41375-021-01406-y","article-title":"Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"36","author":"Zanotti","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.06.005_bib0022","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.06.005_bib0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/cancers15061664","article-title":"Mast cell leukemia: an update with a practical review","volume":"15","author":"Zanelli","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.clml.2024.06.005_bib0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/bloodadvances.2022008292","article-title":"Mast cell leukemia: Clinical and molecular features and survival outcomes of patients in the ECNM Registry","volume":"7","author":"Kennedy","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0026","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.jaip.2022.05.036","article-title":"Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group","volume":"10","author":"Sotlar","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.clml.2024.06.005_bib0027","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","article-title":"Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.clml.2024.06.005_bib0028","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: A sensitive and precise method for KIT D816V quantification in mastocytosis","volume":"64","author":"Greiner","year":"2018","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.clml.2024.06.005_bib0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.005_bib0030","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0031","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","article-title":"Detection of KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications","volume":"28","author":"Jara-Acevedo","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.clml.2024.06.005_bib0032","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3324\/haematol.2019.217950","article-title":"Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis","volume":"105","author":"Greiner","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2024.06.005_bib0033","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.06.005_bib0034","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.06.005_bib0035","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.06.005_bib0036","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1, and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2024.06.005_bib0037","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jahwar","year":"2016","journal-title":"Leukemia"},{"issue":"31","key":"10.1016\/j.clml.2024.06.005_bib0038","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.06.005_bib0039","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.clml.2024.06.005_bib0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.iac.2023.04.003","article-title":"Measuring symptom severity and quality of life in mastocytosis","volume":"43","author":"Pyatilova","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.clml.2024.06.005_bib0041","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J. Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0042","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.005_bib0043","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00277-023-05180-y","article-title":"Response and resistance to cladribine in patients with advanced systemic mastocytosis: A Registry-based analysis","volume":"102","author":"L\u00fcbke","year":"2023","journal-title":"Ann Hematol"},{"issue":"16","key":"10.1016\/j.clml.2024.06.005_bib0044","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.21.01849","article-title":"Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a Registry-based analysis","volume":"40","author":"L\u00fcbke","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.06.005_bib0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2024.06.005_bib0046","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.3390\/cancers14143474","article-title":"Systemic mastocytosis and other entities involving mast cells: a practical review and update","volume":"14","author":"El Hussein","year":"2022","journal-title":"Cancers"},{"issue":"2D","key":"10.1016\/j.clml.2024.06.005_bib0047","article-title":"NCCN Guidelines\u24c7 Insights: Systemic Mastocytosis, Version 3.2024","volume":"22","author":"Gotlib","year":"2024","journal-title":"J Natl Cancer Netw"},{"issue":"40","key":"10.1016\/j.clml.2024.06.005_bib0048","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib is systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2024.06.005_bib0049","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of the phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.06.005_bib0050","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"issue":"26","key":"10.1016\/j.clml.2024.06.005_bib0051","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.06.005_bib0052","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jahwar","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.06.005_bib0053","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and the European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"414","key":"10.1016\/j.clml.2024.06.005_bib0055","doi-asserted-by":"crossref","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.clml.2024.06.005_bib0056","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.clml.2024.06.005_bib0057","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clml.2024.06.005_bib0058","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3390\/ijms22062983","article-title":"Response criteria in advanced systemic mastocytosis: evolution in the era of KIT inhibitors","volume":"22","author":"Shomali","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"Suppl","key":"10.1016\/j.clml.2024.06.005_bib0059","article-title":"P1023: Avapritinib with advanced Systemic Mastocytosis (AdvSM): efficacy and safety analysis from the phase 2 PATHFINDER study with 2-year follow-up","volume":"7","author":"Gotlib","year":"2023","journal-title":"Hemasphere"},{"issue":"21","key":"10.1016\/j.clml.2024.06.005_bib0060","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","article-title":"Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis","volume":"6","author":"Reiter","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl","key":"10.1016\/j.clml.2024.06.005_bib0061","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/01.HS9.0000846924.89785.04","article-title":"P1014: Overall survival in patients with advanced systemic mastocytosis receiving avapritinib versus midostaurin or cladribine","volume":"6","author":"Reiter","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0062","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/bcp.15673","article-title":"A post-marketing pharmacovigilance study of avapritinib: adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database","volume":"90","author":"Rong","year":"2024","journal-title":"Br J Clin Pharm"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0063","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0064","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2022-166986","article-title":"Avapritinib as first-line therapy in patients with advanced systemic mastocytosis: efficacy and safety from the PATHFINDER clinical study","volume":"140","author":"Radia","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.06.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"issue":"Suppl.3","key":"10.1016\/j.clml.2024.06.005_bib0066","article-title":"P1017: Reductions in indolent systemic mastocytosis biomarker burden with avapritinib in the registrational, double-blind placebo-controlled PIONEER trial","volume":"7","author":"Gotlib","year":"2023","journal-title":"Hemasphere"},{"issue":"12_Suppl","key":"10.1016\/j.clml.2024.06.005_bib0067","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/1538-7445.AM2022-147","article-title":"Abstract 147: Bezuclastinib is a differentiated KIT inhibitor that exhibits unique selectivity to KIT A-loop mutations, minimal brain penetration, and favorable pharmacokinetic properties in preclinical models","volume":"82","author":"Guarnieri","year":"2022","journal-title":"Cancer Res"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0068","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2021-152770","article-title":"Preclinical data with KIT D816V inhibitor bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance","volume":"138","author":"Guarnieri","year":"2021","journal-title":"Blood"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0069","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2022-156311","article-title":"Preliminary safety and efficacy from APEX, a phase 2 study of bezuclastinib (CGT9486), a novel, highly selective, potent KIT D816V tyrosine kinase inhibitor, in adults with advanced systemic mastocytosis (AdvSM)","volume":"140","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0070","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2023-178885","article-title":"Safety and efficacy of bezuclastinib (CGT9486), a novel, highly selective, potent KIT D816V tyrosine kinase inhibitor, in patients with advanced systemic mastocytosis (AdvSM): results from part 1 of the phase 2 APEX trial","volume":"142","author":"Vachhani","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.005_bib0071","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2023-178927","article-title":"Initial results from SUMMIT: An ongoing, 3-part, multi-center, randomized, double-blind, placebo-controlled phase 2 clinical study of bezuclastinib in adult patients with nonadvanced systemic mastocytosis","volume":"142","author":"Bose","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.06.005_bib0072","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"2:Suppl\uff0e","key":"10.1016\/j.clml.2024.06.005_bib0073","article-title":"Intial results from SUMMIT: An ongoing, 3-part, multi-center, randomized, double-blind, placebo-controlled phase 2 clinical study of bezuclastinib in adult patients with nonadvanced systemic mastocytosis (nonAdvSM)","volume":"153","author":"Modena","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"13_Suppl","key":"10.1016\/j.clml.2024.06.005_bib0074","article-title":"Abstract CT122: Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers","volume":"81","author":"Dave","year":"2021","journal-title":"Cancer Res"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2023-188904","article-title":"Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: analysis of the HARBOR trial","volume":"142","author":"Tashi","year":"2023","journal-title":"Blood"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0076","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1182\/blood-2022-167410","article-title":"AZURE: a phase 1\/2 study of BLU-263 as monotherapy and in combination with azacitidine in patients with advanced systemic mastocytosis","volume":"140","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.06.005_bib0077","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/hematology.2022000368","article-title":"Available and emerging therapies for bone fide advanced systemic mastocytosis and primary eosinophilic neoplasms","volume":"2022","author":"Gotlib","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2024.06.005_bib0078","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2021-150872","article-title":"Effective control of advanced systematic mastocytosis with avapritinib: mutational analysis from the EXPLORER clinical study","volume":"138","author":"Deininger","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.005_bib0079","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0080","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton's tyrosine kinase inhibition\u2212an emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"17","author":"Mendes-Bastos","year":"2022","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.clml.2024.06.005_bib0081","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1074\/jbc.M110.165613","article-title":"Absence of Tec family kinases interleukin-2 inducible T cell kinase (Itk) and Bruton's tyrosine kinase (Btk) severely impairs Fc\u03b5RI-dependent mast cell responses","volume":"286","author":"Iyer","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2024.06.005_bib0082","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/vco.12520","article-title":"Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells","volume":"1794","author":"Gamperl","year":"2019","journal-title":"Vet Comp Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.06.005_bib0083","first-page":"4759","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2024.06.005_bib0084","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"15","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clml.2024.06.005_bib0086","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/ar3198","article-title":"Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases","volume":"12","author":"Pamuk","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.clml.2024.06.005_bib0087","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/eji.201141502","article-title":"Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo","volume":"41","author":"Wex","year":"2011","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.clml.2024.06.005_bib0088","first-page":"1135","article-title":"CSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin","volume":"176","author":"Ramirez-Molina","year":"2019","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2024.06.005_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107320","article-title":"A novel natural Syk inhibitor suppresses IgE-mediated mast cell activation and passive cutaneous anaphylaxis","volume":"146","author":"Wang","year":"2024","journal-title":"Bioorg Chem"},{"issue":"20","key":"10.1016\/j.clml.2024.06.005_bib0090","doi-asserted-by":"crossref","first-page":"15125","DOI":"10.3390\/ijms242015125","article-title":"Antibody-based and cell therapies for advanced mastocytosis: established and novel concepts","volume":"24","author":"Valent","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2024.06.005_bib0091","first-page":"699","article-title":"Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: best practice recommendations on behalf of the EBMT practice harmonisation and guidelines committee","volume":"3","author":"McLornan","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.06.005_bib0092","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.06.005_bib0093","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41375-024-02186-x","article-title":"Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: A retrospective analysis of the DRST and GREM Registries","volume":"38","author":"L\u00fcbke","year":"2024","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:39:08Z","timestamp":1736059148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024002398"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}